Clinical Trial

A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-04-27; most recent amendment 2025-09-04.
Status change: Not Yet Recruiting → Recruiting 2022-12-27
Trial Details
NCT Number NCT05357651
Lead Sponsor L & L Bio Co., Ltd., Ningbo, China
Conditions Solid Tumor, Lymphoma
Enrollment 100 participants
Start Date 2022-08-12
Primary Completion 2026-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-11